According to this announcement it is "the" top seller in Australia- Holly crap shareholders will all be rich!!! I would like to see how they measured that? Perhaps a statistics expert broke down a subset of a subset of a subset?.
Question for CM - Clarify how she came to that conclusion?
"and has been launched inmultiple markets, including Australia, where the product is the top-selling topical BV treatment.
So they kept it ongoing incase a precedent was formed by another drug/ company that they could piggyback on rather than coming clean ages ago?
So what is a suitable trial worth and with a " market leader top seller" why would you not expend the cash? What could be abetter investment? What hurdle could FDA set that would complicate a trial so much?
Two positives - does this mean the end of JF consultancy? No more outflow of $ on consultants and FDA ?
Ann: VivaGel BV US FDA Appeal Outcome, page-16
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.002(2.04%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 9.9¢ | 10.0¢ | 9.8¢ | $18.37K | 184.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1544 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 90000 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |